The Pharmacology Core facility will be responsible for the design, execution, and analysis of experiments that address metabolic stability, general in i//Vo toxicity, pharmacokinetics, and in vivo efficacy of anti-cancer compounds generated by this Program Project Grant (PPG). In addition, they will maintain the cell lines, animal resources, and equipment that support these functions. It is anticipated that all four projects of this PPG may potentially have need for the services provided by this Core facility. In addition, the Core will serve as a resourcefor members of the UT Southwestern Medical Center (UTSWMC) Comprehensive Cancer Center needing assistance with pharmacological assays. Since there are no other facilities here that can provide in-depth analysis of the behavior of novel small molecules in an in vivo setting, the creation of such a shared resource has the potential to impact the future development of translational cancer research at UTSWMC. The services provided by the Core facility will include: in vitro screening of compounds against a broad tumor panel;characterization of the metabolic stability of individual compounds in vitro and identification of metabolites as necessary;assessment of the solubility, plasma protein binding, and absorption characteristics of compounds in vitro;determination of the maximum in vivo tolerated dose and a preliminary assessment of toxicity;assessment of the distribution of compounds in small rodent models (pharmacokinetics);and development of mouse xenograft or other appropriate models for assessment of compound efficacy in vivo. The Pharmacology Core facility will work closely with PPG chemists to refine the structure of individual compounds so that characteristics that favor optimal efficacy in vivo will be maximized. There is an urgent need for new therapeutics to fight cancer, which in 2005 was responsible for over 500,000 deaths. The overall goal of this Program Project grant (PPG) is to discover and characterize synthetic, small molecule compounds that may be effective in the treatment of this disease. The Pharmacology Core facility will perform in vitro and in vivo measurements of compound concentration, toxicity, and efficacy in animal models. The overall goal of the Core is to guide chemical synthesis efforts of PPG projects in such a way that novel molecules with the best chance of clinical success in cancer patients are generated.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA095471-09
Application #
8117618
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
9
Fiscal Year
2010
Total Cost
$191,054
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Qi, Chen; Wang, Xin; Shen, Zhirong et al. (2018) Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells. Cell Res 28:544-555
Zhang, Lu; Theodoropoulos, Panayotis C; Eskiocak, Ugur et al. (2016) Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer. Sci Transl Med 8:361ra140
Guo, Yirui; Scheuermann, Thomas H; Partch, Carrie L et al. (2015) Coiled-coil coactivators play a structural role mediating interactions in hypoxia-inducible factor heterodimerization. J Biol Chem 290:7707-21
Scheuermann, Thomas H; Stroud, Daniel; Sleet, Christopher E et al. (2015) Isoform-Selective and Stereoselective Inhibition of Hypoxia Inducible Factor-2. J Med Chem 58:5930-41
Rose, Tristan E; Lawson, Kenneth V; Harran, Patrick G (2015) Large ring-forming alkylations provide facile access to composite macrocycles. Chem Sci 6:2219-2223
Zhang, Yongyou; Desai, Amar; Yang, Sung Yeun et al. (2015) TISSUE REGENERATION. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. Science 348:aaa2340
Iscla, Irene; Wray, Robin; Wei, Shuguang et al. (2014) Streptomycin potency is dependent on MscL channel expression. Nat Commun 5:4891
Rogers, Jamie L; Bayeh, Liela; Scheuermann, Thomas H et al. (2013) Development of inhibitors of the PAS-B domain of the HIF-2ýý transcription factor. J Med Chem 56:1739-47
Wang, Changguang; Williams, Noelle S (2013) A mass balance approach for calculation of recovery and binding enables the use of ultrafiltration as a rapid method for measurement of plasma protein binding for even highly lipophilic compounds. J Pharm Biomed Anal 75:112-7
Kilgore, Jessica A; Du, Xinlin; Melito, Lisa et al. (2013) Identification of DNMT1 selective antagonists using a novel scintillation proximity assay. J Biol Chem 288:19673-84

Showing the most recent 10 out of 67 publications